<DOC>
	<DOCNO>NCT00849875</DOCNO>
	<brief_summary>The purpose clinical trial find successfully , patient progressive metastatic cutaneous melanoma , able develop immune response injection immunotherapeutic product GSK1572932A give combination dacarbazine evaluate safety combination .</brief_summary>
	<brief_title>A Study Safety Clinical Activity Immunotherapy Plus Chemotherapy Metastatic Melanoma Patients</brief_title>
	<detailed_description>This Protocol Posting update follow amendment 3 , date 16 October 2009 . The section impact : - Enrollment , number subject - Outcome measure - Exclusion criterion</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Male female patient histologically proven , measurable metastatic cutaneous melanoma 2 . Written inform consent obtain patient performance protocolspecific procedure . 3 . Patient &gt; = 18 year age time signature Informed Consent . 4 . The patient 's tumor show expression MAGEA3 antigen , detect ReverseTranscription Polymerase Chain Reaction ( RTPCR ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . The patient normal organ function . 7 . If patient female , must nonchildbearing potential , , childbearing potential , must practice adequate contraception 30 day prior administration study treatment , negative pregnancy test continue precaution study treatment period 2 month completion treatment administration series . 8 . In view investigator , patient comply requirement protocol . 1 . The patient time receive systemic ( bio ) chemotherapy . 2 . The patient schedule receive anticancer treatment specify protocol , include limited ( bio ) chemotherapy , immunomodulating agent radiotherapy . 3 . The patient require concomitant treatment systemic corticosteroid , immunosuppressive agent . 4 . The patient receive cancer immunotherapeutic contain MAGEA3 antigen cancer immunotherapeutic his/her metastatic disease . 5 . The patient receive investigational nonregistered drug vaccine study medication within 30 day precede first dose study treatment , plan receive drug study period . 6 . The patient ( ) previous concomitant malignancy site , except effectively treat malignancy consider investigator highly likely cure . 7 . History allergic disease reaction likely exacerbate component study investigational product . 8 . The patient autoimmune disease , limited , multiple sclerosis , lupus , inflammatory bowel disease . Patients vitiligo exclude . 9 . The patient family history congenital hereditary immunodeficiency . 10 . The patient know positive Human Immunodeficiency Virus ( HIV ) . 11 . The patient psychiatric addictive disorder may compromise his/her ability give inform consent , comply trial procedure . 12 . The patient concurrent severe medical problem , unrelated malignancy , would significantly limit full compliance study expose patient unacceptable risk . 13 . For female patient : patient pregnant lactating . 14 . The patient uncontrolled bleed disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ASCI</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>Cancer immunotherapeutic</keyword>
	<keyword>MAGE-A3</keyword>
	<keyword>Malignant melanoma</keyword>
</DOC>